Bone and TNF in rheumatoid arthritis: clinical implications

Maria Manara, Luigi Sinigaglia

ABSTRACT
Experimental data have demonstrated that tumour necrosis factor (TNF) plays a significant role in systemic and local bone loss related to rheumatoid arthritis (RA). In clinical studies on patients with RA, treatment with TNF inhibitors was able to arrest systemic bone loss assessed by bone mineral density and bone turnover markers, but there is scarce evidence of a clinically meaningful effect of TNF inhibition in preventing fractures. TNF inhibitors showed a higher efficacy in reducing radiographic progression related to the disease compared to methotrexate in randomised clinical trials. Data from observational studies seem to confirm the effectiveness of anti-TNF therapy in reducing joint damage evolution.

Key messages
What is already known about this subject?
▸ Tumour necrosis factor (TNF) can induce bone loss in rheumatoid arthritis. Treatment with TNF inhibitors may exert a protective effect on systemic and local bone loss related to the disease.

What does this study add?
▸ This review summarises the results of published studies assessing the effect of treatment with TNF inhibitors on systemic and local bone loss in rheumatoid arthritis. Overall, published data support the efficacy of anti-TNF therapy in reducing radiographic progression, but data on fracture prevention are scarce.

How might this impact on clinical practice?
▸ Since evidences on the effect of anti-TNF treatment in preventing fractures are still scarce, clinicians should be made aware of the need for a proper treatment of systemic bone loss in patients with rheumatoid arthritis.
Bone erosion represents the most distinctive radiographic sign of joint damage in RA and it has not only diagnostic, but also prognostic value, since it is utilised as one of the main outcome measures in clinical trials. The development of bone erosions is strictly related to local joint inflammation and often preceded by periarticular osteoporosis on radiographs. The introduction of MRI in clinical practice allowed for identification of an altered signal in the subchondral bone adjacent to the joint areas, corresponding to a bone marrow infiltrate of inflammatory cells on histology examination. These lesions have been demonstrated to predict subsequent erosions. Therefore, in addition to the classical view of an inflamed synovial tissue penetration of bone from ‘outside’, a role of bone marrow inflammation has also been hypothesised in the pathogenesis of erosions.

Clinical studies showing an association between systemic osteoporosis and erosion development may suggest a common pathogenic mechanism for systemic and local bone loss. Since the identification of OC in the synovial inflammatory tissue of patients with RA the idea that these cells may play a fundamental role in the pathogenesis of joint damage has been postulated. TNF produced by the inflamed synovium can induce OC-mediated bone damage in the joint by directly triggering OC differentiation or promoting it indirectly by stimulating RANKL expression on synovial fibroblast and T cell. Experimental data on mice with induced arthritis showed that erosive damage is strictly related to OC activity, since RANKL knockout mice developed only joint inflammation but no erosions. A local inhibition of bone formation mediated by TNF-induced production of DKK-1 by synovial fibroblasts could also account for a defective repair of bone erosions in patients with RA (figure 1).

TNF INHIBITION AND SYSTEMIC BONE LOSS

A number of clinical studies were conducted to assess the effect of treatment with TNF inhibitors on bone mineral density (BMD) in patients with RA (table 1).

Almost all studies demonstrated that treatment with anti-TNF could arrest the decrease of BMD related to the disease and sometimes even increase BMD values. Conflicting findings emerged from studies in which the effect on BMD was compared between clinical responders and non-responders to the treatment: in a cohort study on patients treated with infliximab and methotrexate (MTX), a positive effect on BMD was found only in clinical responders, while in another study with a historical group of controls a beneficial effect on BMD values was also found in clinical non-responders. These data raise the question of whether the effect of anti-TNF treatment on BMD is due only to clinical inflammation suppression or is also related to a specific TNF inhibition. The findings of the BeSt study of similar BMD variations among patients treated with infliximab and other non-biological disease-modifying antirheumatic drugs (DMARDs) combinations suggest that the beneficial effect of anti-TNF treatment could be mainly related to systemic inflammation suppression. Moreover, previous studies showed that, in patients treated with low dosages of glucocorticoids, the negative effect of these drugs on bone metabolism is somehow counteracted by the benefits derived from the suppression of inflammation: this observation further supports the hypothesis that the beneficial effect of the treatment of RA on bone could mainly be related to the control of inflammation.

Other studies focused on the effect of TNF inhibition on bone turnover markers: an overall positive effect on bone turnover markers was observed, with an increase in bone formation and a decrease in bone resorption markers (table 2).

Serum levels of RANKL and the RANKL/OPG ratio were tested in different cohorts and an overall reduction of these markers of OC activity was found in patients treated with TNF inhibitors. More recently, a relative reduction of serum levels of DKK1 was documented after treatment with anti-TNF.

Despite the existence of a large amount of data on surrogate end points of bone fragility, data on fractures in patients treated with anti-TNF are scarce. In a recent study on 9020 patients with RA identified from administrative databases, the risk of fractures did not differ between patients treated with TNF inhibitors or other DMARDs, and only a concomitant treatment with >10 mg/day of prednisone equivalent was a significant predictor of fracture. In another population-based cohort study, the risk of non-vertebral osteoporotic fractures was not different between subjects treated with TNF inhibitors or other DMARDs. These findings are in line with data from a large population-based study in Canada, which showed no reduction in fracture rates among patients with RA between 2003 and 2008.

TNF INHIBITION AND LOCAL BONE LOSS

In addition to the effects of TNF inhibition on systemic bone loss, a few studies have evaluated the influence of the treatment on local bone loss measured by metacarpal BMD (table 1). Most of them found that the stabilisation of spine or hip BMD values after treatment with TNF inhibitors was not accompanied by a similar effect on hand BMD. However, the real significance of local BMD measurement still needs to be defined.

The main manifestation of local bone damage in RA is the development of erosions and joint destruction, which can be measured in terms of radiographic progression by different scoring methods on X-rays. This issue was investigated in most of the controlled trials performed to assess the efficacy of TNF inhibitor therapy, since the prevention of joint damage is one of the primary goals of the treatment. Therefore, a great deal
of data is available on the higher efficacy of anti-TNF treatment compared to conventional DMARDs (namely MTX) in reducing radiographic damage progression.\textsuperscript{46–53} In a meta-analysis of trials that assessed the efficacy of different biological therapies in terms of radiographic damage prevention, the treatment with biological drugs was shown to be more efficacious than MTX alone both in patients in early stages of the disease and in those with long-standing RA; however, owing to a high heterogeneity of study populations, an indirect comparison between different biologics was not feasible.\textsuperscript{54}

**Table 1** Main results of studies assessing the effect of anti-TNF treatment on bone mineral density in patients with rheumatoid arthritis

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Drug</th>
<th>Patients (n)</th>
<th>Controls (n)</th>
<th>Follow-up (months)</th>
<th>Femoral BMD</th>
<th>Lumbar BMD</th>
<th>Hand BMD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pts</td>
<td>Ctr</td>
<td></td>
<td>Pts</td>
<td>Ctr</td>
<td>Pts</td>
</tr>
<tr>
<td>Lange</td>
<td>2005</td>
<td>INF</td>
<td>26</td>
<td>–</td>
<td>12</td>
<td>↑</td>
<td>–</td>
<td>↑</td>
</tr>
<tr>
<td>Vis</td>
<td>2005</td>
<td>INF</td>
<td>36</td>
<td>–</td>
<td>12</td>
<td>↓ (NS)</td>
<td>–</td>
<td>↑</td>
</tr>
<tr>
<td>Seriolo</td>
<td>2006</td>
<td>INF/ETA</td>
<td>9/11</td>
<td>10</td>
<td>6</td>
<td>↑ (NS)</td>
<td>↑ (NS)</td>
<td>↓ (NS)</td>
</tr>
<tr>
<td>Vis</td>
<td>2006</td>
<td>INF</td>
<td>102</td>
<td>99</td>
<td>12</td>
<td>↔</td>
<td>–</td>
<td>↔</td>
</tr>
<tr>
<td>Marotte</td>
<td>2007</td>
<td>INF</td>
<td>90</td>
<td>99</td>
<td>12</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Chopin</td>
<td>2008</td>
<td>INF</td>
<td>48</td>
<td>–</td>
<td>12</td>
<td>↔</td>
<td>–</td>
<td>↔</td>
</tr>
<tr>
<td>Guler-Yuksel</td>
<td>2008</td>
<td>INF</td>
<td>88</td>
<td>254</td>
<td>12</td>
<td>↓ (NS)</td>
<td>↓ (NS)</td>
<td>↓ (NS)</td>
</tr>
<tr>
<td>Haugeberg</td>
<td>2009</td>
<td>INF</td>
<td>10</td>
<td>10</td>
<td>12</td>
<td>↔</td>
<td>↓ (NS)</td>
<td>↓ (NS)</td>
</tr>
<tr>
<td>Hoff</td>
<td>2009</td>
<td>ADA</td>
<td>261+261</td>
<td>246</td>
<td>24</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Wijbrandts</td>
<td>2009</td>
<td>ADA</td>
<td>50</td>
<td>–</td>
<td>12</td>
<td>↔</td>
<td>–</td>
<td>↔</td>
</tr>
<tr>
<td>Eekman</td>
<td>2011</td>
<td>INF</td>
<td>52</td>
<td>–</td>
<td>24</td>
<td>↔</td>
<td>↑</td>
<td>–</td>
</tr>
<tr>
<td>Hoff</td>
<td>2011</td>
<td>ADA</td>
<td>214</td>
<td>188</td>
<td>12</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Bertoldi</td>
<td>2013</td>
<td>ETA</td>
<td>5</td>
<td>7</td>
<td>12</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Dischereit</td>
<td>2013</td>
<td>INF</td>
<td>18</td>
<td>–</td>
<td>24</td>
<td>↔</td>
<td>–</td>
<td>↔</td>
</tr>
<tr>
<td>Krieckaert</td>
<td>2013</td>
<td>ADA</td>
<td>184</td>
<td>–</td>
<td>48</td>
<td>↓</td>
<td>–</td>
<td>↔</td>
</tr>
<tr>
<td>Szentpetyer</td>
<td>2013</td>
<td>ETA/ADA/INF</td>
<td>35</td>
<td>–</td>
<td>36</td>
<td>↓</td>
<td>↔</td>
<td>–</td>
</tr>
<tr>
<td>Okano</td>
<td>2014</td>
<td>INF/ETA</td>
<td>90/27</td>
<td>102</td>
<td>12</td>
<td>↔</td>
<td>↔</td>
<td>–</td>
</tr>
</tbody>
</table>

ADA, Adalimumab; BMD, bone mineral density; Ctr, controls; ETA, etanercept; INF, infliximab; NS, not significant; Pts, patients.
Given that patients included in controlled trials are usually selected by strict inclusion criteria and therefore not fully representative of a real-life situation, some cohort studies were performed assessing the effect of anti-TNF on radiographic damage in subjects included in clinical registries. In these observational studies, the rate of radiographic progression in patients treated with TNF inhibitors was compared with that of subjects treated with other DMARDs, and a decreased radiographic progression after the initiation of anti-TNF treatment was a common finding.\(^{30-37}\)

Recently, the first biosimilar anti-TNF inhibitor was approved by the EMA for the treatment of RA: CTP-13, a biosimilar infliximab, whose biosimilarity to innovator infliximab in the treatment of RA was demonstrated in a randomised, double-blind, prospective clinical trial. In the PLANETRA study, biosimilar infliximab showed an efficacy similar to that of innovator infliximab in obtaining an ACR20 response at 30 weeks in patients with RA concomitantly treated with MTX, with a comparable safety and immunogenicity profile.\(^{38}\)

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Drug</th>
<th>Patients (n)</th>
<th>RANKL</th>
<th>OPG</th>
<th>RANKL/OPG</th>
<th>OC</th>
<th>PINP</th>
<th>CTX</th>
<th>NTX</th>
<th>DPD</th>
<th>BAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ziołkowska</td>
<td>2002</td>
<td>INF</td>
<td>21</td>
<td>↓</td>
<td>↔</td>
<td>↔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vis</td>
<td>2003</td>
<td>INF</td>
<td>68</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lange</td>
<td>2005</td>
<td>INF</td>
<td>26</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seriolo</td>
<td>2006</td>
<td>INF/ETA</td>
<td>9/11</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Torikai</td>
<td>2006</td>
<td>INF</td>
<td>17</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vis</td>
<td>2006</td>
<td>INF</td>
<td>102</td>
<td>↓</td>
<td>↔</td>
<td>↓</td>
<td></td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marotte</td>
<td>2007</td>
<td>INF</td>
<td>90</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chopin</td>
<td>2008</td>
<td>INF</td>
<td>48</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yasunori</td>
<td>2008</td>
<td>ETA</td>
<td>30</td>
<td>↓</td>
<td>↔</td>
<td>↓</td>
<td></td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discheriet</td>
<td>2013</td>
<td>INF</td>
<td>18</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Korczowska</td>
<td>2013</td>
<td>INF</td>
<td>36</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Széntpetery</td>
<td>2013</td>
<td>INF/ETA/ADA</td>
<td>35</td>
<td>↓</td>
<td>↔</td>
<td>↔</td>
<td></td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lim</td>
<td>2014</td>
<td>ETA</td>
<td>33</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Okano</td>
<td>2013</td>
<td>INF/ETA</td>
<td>90/27</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2 Main results of studies assessing the effect of anti-TNF treatment on markers of bone turnover in RA

ADA, Adalimumab; BAP, bone alkaline phosphatase; CTX, C- telopeptide of type I collagen; DPD, deoxypyridinoline; ETA, etanercept; INF, infliximab; NTX, N- telopeptide of type I collagen; OC, osteocalcin; OPG, osteoprotegerin; PINP, N-terminal propeptide of type I collagen; RANKL, receptor activator of the NFκappaB ligand.

CONCLUSIONS

Despite extensive data on the biological action of TNF on bone, there is scarce evidence that TNF inhibition has a clinically meaningful effect on preventing fractures in patients with RA, and only data on surrogate markers of systemic bone loss are available. More consolidated data are available on the efficacy of anti-TNF therapy in limiting local bone loss and reducing radiographic progression related to the disease.

Competing interests None declared.

Provenance and peer review Commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


Author Year Drug Patients (n) RANKL OPG RANKL/OPG OC PINP CTX NTX DPD BAP

ADA, Adalimumab; BAP, bone alkaline phosphatase; CTX, C- telopeptide of type I collagen; DPD, deoxypyridinoline; ETA, etanercept; INF, infliximab; NTX, N- telopeptide of type I collagen; OC, osteocalcin; OPG, osteoprotegerin; PINP, N-terminal propeptide of type I collagen; RANKL, receptor activator of the NFκappaB ligand.


43. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, ...


